Welcome to our dedicated page for BRISTOL MYERS SQUIBB CO SEC filings (Ticker: BMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bristol-Myers Squibb Company SEC filings document the company’s pharmaceutical operating results, investor presentations, governance matters, registered securities and debt activity. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD presentations, annual-meeting vote results and other material events, including note offerings and tender-offer disclosures tied to the company’s capital structure.
The company’s proxy materials cover board elections, executive compensation, shareholder voting matters and corporate governance. Its registered securities disclosures include common stock, Celgene contingent value rights and multiple exchange-listed notes. Form 15 records also document the termination of registration for a $2 convertible preferred stock class with no holders of record, while other reporting obligations remain tied to listed securities.
Bristol Myers Squibb director Phyllis R. Yale received 577.082 Deferred Share Units as a compensation award. The grant was valued at $60.65 per unit and is linked to an equal number of underlying common shares. Following this award, she holds 43,903.777 Deferred Share Units in total.
The units will convert into common stock when she leaves the board or on a future date she previously chose. Her balance includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Theodore R. Samuels II received a grant of 845.012 Deferred Share Units as compensation. These units are tied to Bristol Myers Squibb common stock at a reference price of $60.65 per unit.
Each Deferred Share Unit converts into one share of common stock when his board service ends or on a future date he previously selected. Following this award, he holds a total of 68,727.516 Deferred Share Units, which also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Derica W. Rice received a grant of 638.912 Deferred Share Units on common stock. The award is classified as a grant or other acquisition, not an open-market purchase or sale. Each unit will convert into one share of common stock upon settlement.
The Deferred Share Units become settleable when Rice ceases to be a director or at a future date previously specified. Following this grant, Rice holds a total of 39,963.721 Deferred Share Units, which include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Michael R. McMullen received a grant of Deferred Share Units as board compensation. On March 31, 2026, he was awarded 577.082 Deferred Share Units, with a reference price of $60.65 per unit.
Each unit will convert into one share of common stock upon settlement, which occurs when he ceases to be a director or on a future date he previously selected. After this award, he holds 15,556.771 Deferred Share Units, including deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol Myers Squibb director Peter J. Arduini received a grant of 577.082 Deferred Share Units, each tied to common stock valued at $60.65 per unit. After this compensation award, he directly holds a total of 71,435.166 Deferred Share Units.
Each Deferred Share Unit will convert into one share of common stock when the units are settled. Settlement occurs when Arduini ceases to be a director or on a future date he previously specified. The reported holdings include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Bristol-Myers Squibb Company submitted a Form 15 certifying termination of its registration under Section 12(g) of the Securities Exchange Act of 1934 and notifying a suspension of its duty to file reports under Sections 13 and 15(d).
The filing, signed by Amy Fallone, Senior Vice President and Corporate Secretary, is dated March 27, 2026 and lists multiple classes of securities (including $2 Convertible Preferred Stock, Common Stock, Celgene Contingent Value Rights and numerous named notes by coupon and maturity) as covered by the notice.
Bristol-Myers Squibb Co ownership disclosure: The Vanguard Group filed Amendment No. 10 to report 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing states this reporting change follows an internal realignment and disaggregation of certain Vanguard subsidiaries in accordance with SEC Release No. 34-39538, with affected subsidiaries reporting separately after the realignment.
Bristol Myers Squibb is asking shareholders at its virtual May 5, 2026 meeting to elect 11 directors, approve an advisory say‑on‑pay vote, adopt a 2026 Stock Award and Incentive Plan, ratify Deloitte & Touche LLP as auditor, and consider a proposal for an independent board chair.
The proxy highlights 2025 execution: the Growth Portfolio generated $26.4 billion in sales, up 17% over 2024, with seven products annualizing above $1 billion. The company reports 18 global regulatory approvals, completion of a $10 billion debt paydown target ahead of schedule, and a dividend raised for the 16th consecutive year.
Board materials emphasize strong governance, with 10 of 11 director nominees independent, active board refreshment, majority voting with resignation policies, extensive risk oversight, and integration of sustainability and social impact goals into strategy and executive incentives, including expanded use of AI in R&D and operations.
Bristol Myers Squibb reported that Benjamin Hickey, President of the RayzeBio organization, received equity-based awards on March 10, 2026. He was granted 11,429 market share units and 17,143 performance shares, each tied to Bristol Myers Squibb common stock.
Each market share unit converts into shares based on a payout factor linked to total shareholder return, with a minimum payout factor of 80% and a maximum of 225%. These market share units cliff vest on the third anniversary of the grant date, subject to Board certification of performance. Each performance share converts into one share of common stock upon distribution in the first quarter of 2029, also subject to Board certification of performance results.